Cytokine Panel Design and Analyte Selection
- We pick analytes for your biology, not a catalog panel, with in-house conjugation if kits fall short.
- Singleplex or multiplex, on commercial kits or antibody pairs, matched to the question you are asking.
The failure here is always the bottom of the curve: half your samples fall below LLOQ on the analytes that matter, and the panel returns nothing usable. So we give you a route through the platforms rather than a platform. Luminex for breadth, MSD S-PLEX for sensitivity, hybrid LC-MS below that.
Where multiplexed cytokine data earns its keep, program by program. The platform or service that carries each panel is linked.
In vitro release risk in PBMC and whole blood before first-in-human dosing
Read moreLongitudinal cytokine profiles through expansion, persistence and toxicity windows
Pharmacodynamic cytokine readouts supporting dose and schedule decisions
Read moreCytokine and inflammatory readouts supporting the safety package for biologics
Read moreAntigen-specific cytokine response profiling for vaccine and adjuvant programs
Read moreInflammatory cytokine panels tracking disease activity and treatment response
Read moreCytokine safety panels in mouse, rat and NHP for IND-enabling toxicology
The analyte that matters most often sits below a panel's floor; escalation solves it
Read more20+Years Of Biomarker And Cytokine Analysis, Since 2003
500+Custom Methods, Including Multiplex Cytokine Panels
Any scope change goes through a pre-approved SOW addendum, so your cost cannot move without an SOW addendum you have already approved. You get a transparent, itemized quote up front, scoped to your analyte panel, matrix and sample count rather than priced off a flat rate. Cytokine method development typically runs two to four weeks, with validation in four to six, and your audited report with full validation detail follows about two weeks after that. You can opt for rolling data and act on results before the report lands. Your samples stay under cold-chain storage and documented chain of custody from arrival, and we work to current FDA guidance unless your program says otherwise.
Three things get you a quote: your analyte panel and which cytokines actually drive your decision, your matrix and available sample volume, and the sensitivity you need at the low end. If you already have a kit, a panel, or prior run data, send what you have and we will scope against it. Just starting out, lean on us, because our cytokine experience fills in the blanks. We will pick the platform for you, standard ELISA, Luminex or MSD multiplex, or S-PLEX where you need femtogram-level reach, and tell you why. You get an itemized quote and a timeline back, scoped against exactly what you sent us.
The ability to work with our timelines to meet deadlines is very much appreciated.
There is also a willingness to develop new services to meet our needs even if not currently offered.
NorthEast BioLab goes the extra mile. We look forward to more meaningful collaborations.
NorthEast BioLab offers a science-based, hands-on approach to the latest bioanalytical platforms
NorthEast BioLab’s scientists deliver high-quality data on time and within budget
We found their integrity as refreshing as readiness to provide creative scientific input and high-quality data
20+ years of cytokine and PD biomarker work on immuno-oncology, cell therapy and vaccines.
Cytokines are an integral part of our immune system that helps us respond to diseases. So, what are cytokines? Let us first define cytokines…
We confirm your analytes are measurable in your matrix at the low end your study needs.
Itemized scope with every analyte in the panel priced, not a flat panel rate.
Baseline established, spike recovery and dilution linearity resolved, interference cleared.
Two to four weeks to develop, four to six to validate, fit-for-purpose or full GxP.
Panels run in complete batches, with every analyte checked against its own QC range.
Every analyte reported with its own curve and QC record, not one summary for the panel.
A panel that quietly drops four analytes is not a twenty-plex. Linearity and recovery are set per analyte, and you hear which will not hold up first.
Answers to additional Cytokine Analysis And Biomarker Assay questions popular among our potential sponsors.